Approvals, Conferences and Steady Numbers - Research Report on Allergan, Orexigen, ISIS, The Medicines Company, and Akron
Editor Note: For more information about this release, please scroll to bottom
28 Nov, 2013, 08:00 ET
NEW YORK, November 28, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Allergan, Inc. (NYSE: AGN),
Orexigen Therapeutics, Inc. (NASDAQ: OREX), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS), The Medicines Company (NASDAQ: MDCO), and Akorn, Inc. (NASDAQ: AKRX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Allergan, Inc. Research Report
On November 25, 2013, shares of Allergan, Inc. (Allergan) dropped 0.68% to $97.90 at the end of trading. Over the previous three trading sessions, shares of Allergan dropped 0.70% compared to the Dow Jones Industrial Average which gained 1.08% during the same period. The Full Research Report on Allergan, Inc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Orexigen Therapeutics, Inc. Research Report
On November 25, 2013, Orexigen Therapeutics, Inc. (Orexigen) reported that it will resubmit the Contrave® New Drug Application (NDA) to the United States Food and Drug Administration (FDA) in the next few weeks with potential approval by June 2014, a move based on the successful results of the interim analysis of the Light Study that were announced through the same release. Michael Narachi, CEO of Orexigen stated, "The interim analysis of the Light Study clearly achieved the goal set by the FDA. The resubmission will contain an unprecedented amount of cardiovascular outcomes data for an obesity therapeutic, and we are confident these data will support a favorable benefit: risk assessment for Contrave." According to the Company, the FDA had previously agreed that if the interim analysis meets the specified criteria to exclude cardiovascular risk, Contrave could be approved. The Full Research Report on Orexigen Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
ISIS Pharmaceuticals, Inc. Research Report
On November 25, 2013, ISIS Pharmaceuticals, Inc. (ISIS) announced its participation at the upcoming 2013 Deutsche Bank BioFEST on Monday, December 2, 2013 in Boston, MA. ISIS reported that a Company overview will be presented by ISIS' management at 8:25 a.m. ET that day, wherein a live audio webcast will be available at ISIS' website. A replay will also be available within 48 hours and will be archived for a limited time. The Full Research Report on ISIS Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
The Medicines Company Research Report
On November 21, 2013, the European Medicines Agency (EMA) accepted for review a marketing authorization application (MAA) for The Medicines Company's investigational hemostatic agent Fibrocaps (human plasma-derived fibrinogen and thrombin) - indicating the start of the review process in the European Union for Fibrocaps. The Company informed that Fibrocaps was studied in the 719-patient Phase III FINISH-3 clinical trial as an adjunct to hemostasis in patients undergoing surgical procedures when control of mild or moderate bleeding by conventional surgical techniques is ineffective or impractical. According to the Company, it anticipates submitting a biologics license application (BLA) with the US FDA in Q1 2014. The Medicines Company also plans to submit a 510(k) application with the FDA for the complementary spray delivery device to assist surgeons in the accurate application of the dry powder Fibrocaps. The Company further reported that the device was recently granted a European CE mark. The Full Research Report on The Medicines Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Akorn, Inc. Research Report
On November 25, 2013, shares of Akron, Inc. (Akron) closed at $25.39, indicating a 3.21% rise. Akron's shares rose steadily over the past three trading sessions at 8.13% while the Nasdaq composite gained 1.87% during the same period. The Full Research Report on Akorn, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner
Share this article